- Home
- IGI vs SLGL Comparison
IGI vs SLGL Comparison
Compare IGI & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IGI | SLGL |
|---|---|---|
| Founded | 2009 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.8M | 117.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | IGI | SLGL |
|---|---|---|
| Price | $16.46 | $56.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 33.9K | 23.6K |
| Earning Date | 01-01-0001 | 11-20-2025 |
| Dividend Yield | ★ 4.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,970,000.00 |
| Revenue This Year | N/A | $122.71 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $15.13 | $4.02 |
| 52 Week High | $17.79 | $75.00 |
Technical Indicators
Market Signals| Indicator | IGI | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 50.44 | 53.07 |
| Support Level | $16.38 | $60.20 |
| Resistance Level | $16.55 | $75.00 |
| Average True Range (ATR) | 0.09 | 7.13 |
| MACD | 0.01 | -0.23 |
| Stochastic Oscillator | 43.16 | 40.76 |
Price Performance
Historical ComparisonAbout IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.